Davenport & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Davenport & Co’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,363	Closed	-$929K	–	691
2018 Q3	$929K	Sell	11,363 -1,000	-8%	-$70.5K	0.01%	330
2018 Q2	$432K	Hold	12,363	–	–	0.01%	478
2018 Q1	$254K	Buy	12,363 +1,000	+9%	+$25.7K	﹤0.01%	591
2017 Q4	$322K	Hold	11,363	–	–	﹤0.01%	538
2017 Q3	$353K	Hold	11,363	–	–	﹤0.01%	505
2017 Q2	$360K	Sell	11,363 -11,225	-50%	-$276K	﹤0.01%	495
2017 Q1	$493K	Hold	22,588	–	–	0.01%	408
2016 Q4	$493K	Buy	22,588 +11,225	+99%	+$284K	0.01%	409
2016 Q3	$300K	Hold	11,363	–	–	﹤0.01%	484
2016 Q2	$224K	Buy	+11,363	New	+$221K	﹤0.01%	521

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Davenport & Co's RETA Position: Q4 2018 in Review

Davenport & Co sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2018, closing a stake of 11,363 shares — an estimated $929K sold.

Davenport & Co first reported a position in RETA in Q2 2016 and held it in 10 quarters. The position peaked at $929K in Q3 2018. 131 funds tracked by Wall St. Rank hold RETA as of Q4 2018.

Davenport & Co reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2018 after selling out during the quarter.
Davenport & Co sold 11,363 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2018, an estimated $929K.
Davenport & Co first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 10 quarters.
Davenport & Co's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $929K in Q3 2018.
131 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2018.

Based on Davenport & Co's 13F filing for Q4 2018, filed 28 Jan 2019.